Results 1 to 10 of about 11,180 (200)
Ocular myasthenia gravis management [PDF]
Frontiers in NeurologyOcular myasthenia gravis (OMG) has no agreed-upon diagnostic and management criteria, leading to misdiagnoses and often misguided treatments. The purpose of this minireview is to provide guidance to clinicians who encounter possible OMG patients. We cite
Mark J. Kupersmith +2 more
doaj +4 more sources
Neurologijos seminarai, 2022 Myasthenia gravis is a chronic autoimmune neuromuscular disorder typically presenting with variable skeletal muscle fatigue. The most prevalent initial manifestation of myasthenia is ocular myasthenia.
J. Zakaravičiūtė, M. Šerelytė
doaj +4 more sources
Ocular myasthenia: A protean disorder
Survey of Ophthalmology, 1994 Ocular myasthenia is a localized form of myasthenia clinically involving only the extraocular, levator palpebrae superioris, and/or orbicularis oculi muscles. Ocular manifestations can masquerade as a variety of ocular motility disorders, including cranial nerve and gaze palsies.
D A, Weinberg, R L, Lesser, T L, Vollmer
exaly +3 more sources
Delayed Diagnosis of Atypical Presentation of Myasthenia Gravis [PDF]
European Journal of Case Reports in Internal Medicine, 2017 Myasthenia gravis is an autoimmune disorder affecting the neuromuscular junction, resulting in muscle fatiguability and weakness. The pathological characteristics of the disorder include ocular weakness resulting in diplopia and/or ptosis.
Moneeb Sefeldawla Mustafa +3 more
doaj +4 more sources
Ocular myasthenia gravis: A review
Indian Journal of Ophthalmology, 2014 Myasthenia gravis (MG) is a disease that affects the neuro-muscular junction resulting in classical symptoms of variable muscle weakness and fatigability. It is called the great masquerader owing to its varied clinical presentations.
Akshay Gopinathan Nair +3 more
doaj +3 more sources
Add‐On Telitacicept Significantly Improves Outcome of Patients With Refractory Ocular Myasthenia Gravis a Real‐World Case Series [PDF]
Brain and BehaviorIntroduction Refractory ocular myasthenia gravis (MG) represents a significant therapeutic challenge, as conventional immunotherapies often prove ineffective.
Jing Lin +4 more
doaj +2 more sources
Controversies in Ocular Myasthenia Gravis [PDF]
Frontiers in Neurology, 2020 Myasthenia gravis (MG) with symptoms limited to eye muscles [ocular MG (OMG)] is a rare disease. OMG incidence varies according to ethnicity and age of onset.
Amelia Evoli +3 more
doaj +3 more sources
Ocular Myasthenia Gravis: A Current Overview [PDF]
Eye and Brain, 2023 Raed Behbehani
exaly +2 more sources
Frontiers in Pediatrics, 2022 Myasthenia gravis is an organ-specific autoimmune disease. Currently there is no universal guidelines for childhood-onset myasthenia gravis, therefore, treatment strategies are usually based on the guidelines from adult myasthenia gravis patients.
Lifen Yang +6 more
doaj +1 more source
American Journal of Ophthalmology Case Reports, 2023 Purpose: This is a case of myasthenic incomplete ophthalmoplegia mimicking a partial cranial nerve 3 palsy both subjectively and objectively improving after treatment with eculizumab.
Sara L. Weidmayer, Gary Gallagher
doaj +1 more source